V

Viatris
D

VTRS

13.370
USD
0.11
(0.83%)
Market Closed
Volume
261,327
EPS
3
Div Yield
3.62
P/E
-18
Market Cap
15,958,337,100
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    NVO
    NVO
    -3.620
    (-3.44%)
    105.07 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    SNY
    SNY
    0.160
    (0.33%)
    48.275 USD
    More
News

Title: Viatris

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.